Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use TRIUMEQ and TRIUMEQ PD safely and effectively. See full prescribing information for TRIUMEQ and TRIUMEQ PD. TRIUMEQ (abacavir, dolutegravir, and lamivudine) tablets, for oral useTRIUMEQ PD (abacavir, dolutegravir, and lamivudine) tablets for oral suspension Initial U.S. Approval: 2014
Medication labelWhy this: Advisory · dailymed-prescription
TRIUMEQ and TRIUMEQ PD are indicated for the treatment of HIV-1 infection in adults and in pediatric patients aged at least 3 months and weighing at least 6 kg. Limitations of Use: TRIUMEQ and TRIUMEQ PD alone are not recommended in patients with resistance‑associated integrase substitutions or clinically suspected integrase strand transfer inhibitor (INSTI) resistance because the dose of dolutegravir in TRIUMEQ and TRIUMEQ PD is insufficient in these subpopulations. See full prescribing information for TIVICAY (dolutegravir).
- generic_name
- abacavir sulfate, dolutegravir sodium, lamivudine
- product_names
- abacavir sulfate, dolutegravir sodium, lamivudine
- ndc
- 49702-231, 49702-231-13, 49702-258, 49702-258-37, 49702-272, 49702-272-59
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en